02 March 2020 1 Min Read
Gilead to spend almost $5bn acquiring Forty Seven for cancer drug
Forty Seven's experimental drug, magrolimab, is in early studies for cancers including acute myeloid leukaemia and diffuse large B-cell lymphoma
Subscribe to our website to read this article and support quality journalism.
If you’ve already subscribed, simply sign in.
Subscribe Sign In